Clinical Trials Update: July 25, 2006
Crohn's Disease Chronic Lymphocytic Leukemia Sepsis and Septicemia
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study will evaluate an open-label drug in people with moderate-to-severe active Crohn's disease, who fail to respond to infliximab (Remicade ®). Open label treatment means that all participants will receive the study medication. Volunteers 18-75 who have Crohn's disease that's been active during the prior 16 weeks diagnosed by radiologic or endoscopic evaluation may qualify.
The research site is in Wheat Ridge, Co.
Chronic Lymphocytic Leukemia
This study will include people with B-Cell chronic lymphocytic leukemia who have failed or been intolerant / ineligible for treatment with fludarabine and alemtuzumab. Candidates must be at least 18 with tumor cell phenotypes consistent with B-CLL.
The research sites are located worldwide.
Sepsis and Septicemia
People may be eligible for this study if they are at least 18 with a confirmed diagnoses of severe sepsis, have not had extensive third degree burns, are not pregnant and don't intend to become pregnant, are not breastfeeding a child, and are not undergoing immunosuppressive therapy.
The research site is in New Hyde Park, NY.
Copyright 2006 Thomson CenterWatch. All rights reserved.